MedTrace Logo

Special Drug Use Investigation for IMURAN (Azathioprine) Tablet (Pulmones Transplantation)

NCT01381432 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 39

Last updated 2013-05-13

No results posted yet for this study

Summary

This post-marketing surveillance study is to investigate the efficacy and safety of azathioprine tablets in subjects whom lung transplantation is performed.

Conditions

Interventions

DRUG

Azathioprine

At the start of treatment, 2 to 3 mg per kg of body weight each day. For the rest of treatment, 1 to 2 mg per kg of body weight each day.

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Primary Completion
2011-05-31
Completion
2011-05-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01381432 on ClinicalTrials.gov